Topics

Glioblastoma | Treatment | Pharmacotherapy | Antiepileptic Drugs

Home > Publications > Topics > Glioblastoma > Treatment > Pharmacotherapy > Antiepileptic Drugs

Heuer S, Burghaus I, Gose M, Kessler T, Sahm F, Vollmuth P, Venkataramani V, Hoffmann D, Schlesner M, Ratliff M, Hopf C, Herrlinger U, Ricklefs F, Bendszus M, Krieg SM, Wick A, Wick W, Winkler F.
PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
BMC Cancer. 2024 Jan 26;24(1):135. doi: 10.1186/s12885-024-11846-1. PMID: 38279087. Interventional study protocol. ˍ

Vatankhah A, Moghaddam SH, Afshari S, Afshari AR, Kesharwani P, Sahebkar A.
Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme.
Pathol Res Pract. 2024 Oct 3;263:155636. doi: 10.1016/j.prp.2024.155636. PMID: 39395298. Review˰ ˍ

Pak O, Kosianova A, Zaitsev S, Sharma A, Sharma H, Bryukhovetskiy I.
Valproic Acid and Celecoxib Enhance the Effect of Temozolomide on Glioblastoma Cells.
CNS Neurol Disord Drug Targets. 2024 Oct 18. doi: 10.2174/0118715273330268241008220702. PMID: 39428930. Laboratory investigation˰ ˍ

Vychopen M, Güresir A, Basaran AE, Güresir E, Wach J.
Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival.
Neurosurg Rev. 2024 Dec 9;47(1):897. doi: 10.1007/s10143-024-03137-x. PMID: 39653818. Meta-analysis. ˍ

*Panotopoulos C, Athanasiou G, Stavropoulos S, Boutos N, Rao S, Panayotou G, Venkataramana NK, Ronquist G.
Elimination of High-grade Gliomas Through Induced Cytolysis, Elucidated by Two Patient Cases.
Anticancer Res. 2024 Dec 30;45(1):201-207. doi: 10.21873/anticanres.17405. PMID: 39740841. Case report˰ ˍ

Eschen JT, Jensen LL, Hausmann D, Lind ANR, Lukacova S, Weischenfeldt J, Lassen U, Westphal M, Winkler F, Simonsen U, Korshoej AR.
SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol.
BMC Cancer. 2026 Apr 14;26(1):667. doi: 10.1186/s12885-026-15784-y. PMID: 41981510. Trial registration ID: EU-CT: 2025–522605-37–00. ˍ